Molecular mechanisms of chemo‐and radiotherapy resistance and the potential implications for cancer treatment

YP Liu, CC Zheng, YN Huang, ML He, WW Xu… - MedComm, 2021 - Wiley Online Library
Cancer is a leading cause of death worldwide. Surgery is the primary treatment approach for
cancer, but the survival rate is very low due to the rapid progression of the disease and …

(Nano) platforms in bladder cancer therapy: Challenges and opportunities

M Ashrafizadeh, A Zarrabi… - Bioengineering & …, 2023 - Wiley Online Library
Urological cancers are among the most common malignancies around the world. In
particular, bladder cancer severely threatens human health due to its aggressive and …

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Z Shi, L Hao, X Han, ZX Wu, K Pang, Y Dong, J Qin… - Molecular Cancer, 2022 - Springer
Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial
carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic …

Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11

RM Drayton, E Dudziec, S Peter, S Bertz… - Clinical cancer …, 2014 - AACR
Purpose: Resistance to cisplatin-based chemotherapy is a major obstacle to bladder cancer
treatment. We aimed to identify microRNAs (miRNA) that are dysregulated in cisplatin …

Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation

JA Ferreira, A Peixoto, M Neves, C Gaiteiro… - Drug Resistance …, 2016 - Elsevier
Cisplatin-based chemotherapeutic regimens are the most frequently used (neo) adjuvant
treatments for the majority of solid tumors. While platinum-based chemotherapeutic …

Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin

L Miao, Y Wang, CM Lin, Y Xiong, N Chen… - Journal of controlled …, 2015 - Elsevier
The tumor microenvironment (TME) serves as a multidrug resistant center for tumors under
the assault of chemotherapy and a physiological barrier against the penetration of …

Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy

S Guo, Y Wang, L Miao, Z Xu, CM Lin, Y Zhang… - ACS …, 2013 - ACS Publications
Encapsulation of cisplatin (CDDP) into nanoparticles (NPs) with high drug loading and
encapsulation efficiency has been difficult due to the poor solubility of CDDP. However, this …

Glucose metabolism reprogramming in bladder cancer: hexokinase 2 (HK2) as prognostic biomarker and target for bladder cancer therapy

J Afonso, C Gonçalves, M Costa, D Ferreira, L Santos… - Cancers, 2023 - mdpi.com
Simple Summary Urothelial bladder carcinoma entails significant health costs due to the
high recurrence rates and poor response to standard cisplatin-based treatment. The …

Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin

X Wang, F Zhang, XR Wu - Scientific reports, 2017 - nature.com
Chemoresistance to cisplatin is a principal cause of treatment failure and mortality of
advanced bladder cancer (BC). The underlying mechanisms remain unclear, which hinders …

Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer

X Chen, P Gu, R Xie, J Han, H Liu… - Journal of cellular …, 2017 - Wiley Online Library
Heterogeneous nuclear ribonucleoprotein K (hn RNPK) is an essential RNA‐and DNA‐
binding protein that regulates diverse biological events, especially DNA transcription. hn …